Lv52
1230 积分 2021-02-19 加入
Current evidence of rituximab in the treatment of multiple sclerosis
6小时前
已完结
HRA00129-C004, a Novel c-Met Antibody–Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles
7天前
已完结
Guanylyl Cyclase Receptors
12天前
已完结
Guanylyl Cyclases and Signaling by Cyclic GMP
12天前
已关闭
664TiP BEHOLD-2: A phase I/II randomised study evaluating GSK5733584, a B7-H4-targeted antibody-drug conjugate, in combination with anti-cancer agents in patients with advanced solid tumours
18天前
已关闭
Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects
18天前
已完结
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
18天前
已完结
How to Design Next-generation of Antibody-Drug Conjugates for Cancer Treatment: Lessons from Unsuccessful Clinical Trials
1个月前
已完结
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
1个月前
已完结
皖公网安备34019202002308
